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Abstract Background: Combination therapy with a long-acting bronchodilator and an
inhaled corticosteroid (ICS) is recommended in patients with chronic obstructive
pulmonary disease (COPD) who have frequent exacerbations. The efficacy and
tolerability of the combination of budesonide/formoterol have been demonstrated
in patients with COPDwhen administered via the dry powder inhaler (DPI) in a
1-year study andwhen administered via the hydrofluoroalkane (HFA) pressurized
metered-dose inhaler (pMDI) in a 6-month study.
Objective:This study assessed the long-term efficacy and tolerability of budeso-
nide/formoterol HFA pMDI in patients with moderate to very severe COPD.
Methods:This was a 12-month, randomized, double-blind, double-dummy, par-
allel-group, active- and placebo-controlled, multicentre study (NCT00206167) of
1964 patients aged ‡40 years withmoderate to very severeCOPDconducted from
2005 to 2007 at 237 sites in the US, Europe and Mexico. After 2 weeks of
treatment based on previous therapy (ICSs, short-acting bronchodilators allowed),
patients received one of the following treatments twice daily: budesonide/formo-
terol pMDI 160/4.5 mg· two inhalations (320/9mg); budesonide/formoterol
pMDI 80/4.5 mg· two inhalations (160/9 mg); formoterol DPI 4.5 mg · two
inhalations (9 mg); or placebo.
Main outcome measures: The co-primary efficacy variables were pre-dose
forced expiratory volume in 1 second (FEV1) and 1-hour post-dose FEV1.
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Results:Budesonide/formoterol 320/9mg demonstrated greater improvements in
pre-dose FEV1 versus formoterol (p= 0.008), and both budesonide/formoterol
doses demonstrated greater improvements in 1-hour post-dose FEV1 versus
placebo (p< 0.001). The rate of COPDexacerbations was lower in both budeso-
nide/formoterol groups comparedwith formoterol and placebo (p£ 0.004). Both
budesonide/formoterol doses were more effective than placebo (p £ 0.006) for
controlling dyspnoea and improving health status (StGeorge’sRespiratoryQues-
tionnaire). All treatments were generally well tolerated. The incidence of pneumo-
nia was not different for active (3.4–4.0%) and placebo (5.0%) groups.
Conclusions: Budesonide/formoterol pMDI (320/9mg and 160/9mg) improved
pulmonary function and reduced symptoms and exacerbations over 1 year in
patients with moderate to very severe COPD. Only budesonide/formoterol pMDI
320/9mg demonstrated greater efficacy for both co-primary variables compared
with formoterolDPI 9mg. Both budesonide/formoterol pMDI dosages were well
tolerated relative to formoterol and placebo.
Background
In patients with chronic obstructive pulmonary
disease (COPD) and frequent exacerbations, the
combination of a long-acting bronchodilator and an
inhaled corticosteroid (ICS) is recommended.[1]
Budesonide and formoterol delivered via a single
dry powder inhaler (DPI; Symbicort Turbuhaler;
AstraZeneca, Lund, Sweden) have been shown to
improve pulmonary function[2,3] and reduce COPD
exacerbation rates.[2,3] Fixed-combination budeso-
nide/formoterol is available in the US in a hydro-
fluoroalkane pressurized metered-dose inhaler
(pMDI; Symbicort Inhalation Aerosol; Astra-
Zeneca LP, Wilmington, DE, USA). While most
patients with COPD can benefit from either a
pMDIorDPI, the pMDI formulation allows patients
whomay have inadequate peak inspiratory flow for
optimal delivery from aDPI to use the pMDI effec-
tively. A recent 6-month study demonstrated the
efficacy and tolerability of budesonide/formoterol
pMDI in patients with moderate to very severe
COPD.[4] Treatment with budesonide/formoterol
pMDI resulted in significant improvements in pul-
monary function, dyspnoea and health-related quali-
ty of life; however, the duration of the study was
limiting with respect to the analysis of low-frequen-
cy events, such as COPD exacerbations, and pre-
cluded an assessment of safety outcomes with long-
term exposure.[4] In this study, the long-term effi-
cacy and tolerability of two dosage strengths of
budesonide/formoterol pMDI were assessed over




The inclusion criteria were designed to select a
populationwithmoderate to very severeCOPDwith
previous exacerbations (i.e. appropriate candidates
for combination ICS/long-acting b2-adrenoceptor
agonist [LABA] therapy): age ‡40 years, diagnosis
of symptomatic COPD for >2 years, ‡10 pack-year
smoking history, prebronchodilator forced expir-
atory volume in 1 second (FEV1) of £50% of pre-
dicted normal and prebronchodilator FEV1/forced
vital capacity (FVC) of <70%. Patients were to have
a Modified Medical Research Council dyspnoea
scale score of ‡2 and a history of at least oneCOPD
exacerbation requiring oral corticosteroids or anti-
bacterials within 1–12months before the first study
visit. Additional enrolment criteria were the same as
those in a similar 6-month study by Tashkin et al.[4]
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Study Design
This was a randomized, double-blind, double-
dummy, parallel-group, active- and placebo-control-
led, multicentre trial (ClinicalTrials.gov identifier:
NCT00206167) conducted from 2005 to 2007 at 237
sites in the US, Europe and Mexico. The study
protocol was approved by a local institutional re-
view board and ethics committee, and written in-
formed consent was obtained from patients. The
studywas designed to conformwith theDeclaration
of Helsinki, and was consistent with the Internation-
al Conference onHarmonisation andGoodClinical
Practice and applicable regulatory requirements.
After meeting eligibility criteria, patients entered
a 2-week run-in period, during which they received
ICSmonotherapy if previously stable on ICS (alone
or in combination) and ipratropium bromide at a
fixed dose if previously receiving anticholinergics.
Albuterol (salbutamol) was permitted for rescue use
throughout the study.At randomization, all previous
ICSs were discontinued and patients were random-
ized to one of four treatments (figure 1). Patients
whowere treated with ipratropiumbromide during
the run-in period were allowed to continue on it
throughout the study period.Other allowed and dis-
allowed concomitant medications were the same as
those reported in the study by Tashkin et al.[4]
Efficacy Evaluations
The co-primary efficacy variables, measured at
all clinic visits, were pre-dose FEV1 and 1-hour
post-dose FEV1. Additional pulmonary function
variables included pre-dose and 1-hour post-dose
FVCmeasured at all clinic visits, andmorning and
evening peak expiratory flow (PEF) recorded daily
in patient diaries. In a subset of patients (n= 491 of
1964; 25%) who agreed to undergo spirometry test-
ing, 12-hour serial spirometry was performed and
pre-dose and 1-hour post-dose inspiratory capacity
(IC) were collected at randomization andmonths 6
and 12. FEV1 was measured pre-dose and at 5, 15,
30, 60, 120, 180, 240, 360, 480, 600 and 720 min-
utes post-dose. Baseline-adjusted average 12-hour
FEV1 was calculated as the area between the
12-hour post-dose FEV1-over-time curve and the
baseline pre-dose FEV1, divided by observation
time. Spirometrywas performed according toAmer-
icanThoracic Society guidelines.[6] Crapo-predicted
normals for FEV1 were used.
[7]
Secondary efficacy endpoints included COPD
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BUD/FM pMDI 80/4.5 μg x 2 inhalations bid (160/9 μg)
BUD/FM pMDI 160/4.5 μg x 2 inhalations bid (320/9 μg)
−0.5
Fig. 1. Study design. To maintain blinding, patients received both a pressurized metered-dose inhaler (pMDI) and a dry powder inhaler
(DPI) containing either active treatment or double-dummy placebo (PL) as appropriate. This study used formoterol (FM) DPI (Oxis
Turbuhaler, AstraZeneca, Lund, Sweden) as the FM comparator because FM is not available as a hydrofluoroalkane pMDI in the US. A
previous study in asthma patients reported equivalent FM-related bronchodilatory effects when FM was administered in combination with
budesonide (BUD) via pMDI or alone via DPI.[5] Patients were asked to return to the clinic for follow-up visits 3–8 at the end of months 1, 2,
4, 6, 9 and 12, and received a telephone call 4 weeks after the last clinic visit. bid = twice daily; R = randomization.
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scores) and health status, all assessed as previously
described.[4] A COPD exacerbation was defined as
worsening of COPD requiring an oral corticosteroid
or hospitalization.[4] Dyspnoea was assessed daily
before the evening dose of study medication using
the Breathlessness Diary, a validated single-item
component of the Breathlessness Cough and Spu-
tum Scale (BCSS).[8] Health status was assessed at
months 1, 2, 6 and 12 using the StGeorge’s Respira-
tory Questionnaire (SGRQ).[9,10] Sleep score, per-
centage of awakening-free nights (sleep score of 0)
and study rescue medication use were assessed as
previously described by Tashkin et al.[4]
Safety Evaluations
Safety was assessed by adverse event (AE) re-
porting. Pneumonia events were reported by physi-
cians based on theMedical Dictionary for Regulato-
ry Activities (version 10.0) pneumonia-related pre-
ferred terms (pneumonia, bronchopneumonia,
lobar pneumonia or pneumonia staphylococcal). Vi-
tal signs and 12-lead ECGs were evaluated as pre-
viously described by Tashkin et al.[4] Subsets of
patients were assessed for 24-hour urinary cortisol
(n = 179), 24-hour Holter monitoring (n = 520),
bone mineral density (BMD) at the hip and spine
regions (n = 326), and ophthalmological assess-
ments (n= 461), including intraocular pressure and
progression of lenticular opacities. In all patients,
blood and urine samples were collected, and com-
prehensive physical examinations were carried out
at the time of screening and at the end ofmonth 12.
Blood and urine samples were analysed by a central
laboratory (Quest Diagnostics Clinical Laboratories,
Van Nuys, CA, USA). Vital signs, including heart
rate and blood pressure, weremeasured at all study
visits.
Samples to assess 24-hour urinary cortisol levels
were collected in a subset of patients at or before
randomization and within 1 week before the 6- and
12-month visits, and analysed byQuestDiagnostics.
24-Hour Holter monitoring was performed at
screening and months 1 and 4, BMD assessments
(two sets of dual energy x-ray absorptiometry scans
in the hip and spine regions) were performed at
screening and the end ofmonth 12, and ophthalmol-
ogy assessments (intraocular pressure and lenticular
opacities) were performed at screening and the end
of months 6 and 12.
Statistical Analyses
The efficacy analysis set (i.e. intent-to-treat pop-
ulation) included all randomized patients who re-
ceived at least one dose of randomized study med-
ication and contributed sufficient data for at least
one co-primary or secondary efficacy endpoint to be
calculated during the randomized treatment period.
The safety analysis population included all random-
ized patients who received at least one dose of
randomized study medication and from whom any
post-randomization datawere available. For the sub-
sets of patients who underwent serial spirometry,
24-hour urinary cortisol, BMD, 24-hour Holter
monitoring and ophthalmological analyses, analysis
sets were defined as those patients who received at
least one dose of randomized studymedication and
had baseline and on-treatment values for the varia-
ble being assessed. Patients who discontinued pre-
maturely completed final visit (month 12) assess-
ments at the time of discontinuation, followed by the
4-week follow-up. A sample size of approximately
400 patients per treatment group was calculated to
allow 90%power to detect a reduction in the number
of COPD exacerbations of approximately 30%, ad-
justing for overdispersion of 2.3. This sample size
ensured >95% power to detect a difference of 0.10L
in FEV1, given an estimated standard deviation of
0.3 L. All tests were two-sided, with p £ 0.05
considered significant.
The prespecified primary comparators were for-
moterolDPI for pre-dose FEV1 to demonstrate the
contribution of budesonide and placebo for 1-hour
post-dose FEV1. To address issues of multiplicity
relating tomultiple-dose comparisons andmultiple
variables of interest, a fixed-sequence testing proce-
dure was adopted. The primary comparisons
were prespecified as budesonide/formoterol pMDI
320/9 mg compared with (i) placebo for pre-dose
FEV1 and 1-hour post-doseFEV1; and (ii) formoter-
ol DPI 9mg for pre-dose FEV1. If significant differ-
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ences were obtained, comparisons continued with
budesonide/formoterol pMDI 320/9mg compared
with placebo for (i) dyspnoea; (ii) SGRQ total score;
and (iii) number of exacerbations. If significant dif-
ferences were obtained for each of these key secon-
dary variables, the lower dose of budesonide/formo-
terol pMDIwas tested on the co-primary variables,
as previously described, and, if significant differ-
ences were obtained, testing continued with number
of exacerbations, dyspnoea and SGRQ total score
compared with placebo. For all secondary efficacy
variables, the primary comparison was budesonide/
formoterol pMDI versus placebo.
Primary and secondary variables were assessed
as the change from baseline to the average over the
randomized treatment period except for average 12-
hour FEV1, mean FEV1 at 12hours and SGRQ at
end of treatment. Changes from baseline in the co-
primary efficacy variables were analysed via ana-
lysis of co-variance (ANCOVA), adjusting for treat-
ment, country and baseline value. The following
three key secondary efficacy variables were identi-
fied: (i) dyspnoea; (ii) SGRQ total score; and (iii)
exacerbations. Secondary variables were analysed
similar to the co-primary efficacy variables; how-
ever, exacerbation rate (number/patient-treatment
year) was analysed using a Poisson regression
model, adjusted for country and differential
randomization time, and time to first COPDexacer-
bation was described via Kaplan-Meier plot and
analysed using the log-rank test. The number and
percentage of patients experiencing clinically mean-
ingful changes (based on a prespecified minimal
important difference) in dyspnoea were analysed
using the Cochran-Mantel-Haenszel test, adjusting
for country.
Geometric mean 24-hour urinary cortisol levels
at end of treatment were compared between treat-
ment groups using a multiplicative ANCOVA
model.Mean changes from baseline to the average
during the randomized treatment period in 12-lead
ECG, andHolter variables and ophthalmology vari-
ables were analysed using a model similar to that
used for the co-primary variables. BMD variables
(natural logarithm of the analysis timepoint minus
the natural logarithm of the respective baseline
value for hip and spine) were analysed using an
ANCOVAmodel adjusting for country, treatment
and natural logarithm of the baseline value. Other
safety data were summarized using descriptive sta-




Of 1964 randomized patients, 1355 completed
the study (figure 2). Discontinuation was greater
with placebo versus budesonide/formoterol and for-
moterol driven by withdrawal of consent. Time to
discontinuation was significantly (p £ 0.004) pro-
longed in both budesonide/formoterol groups versus
placebo.AEwas themost common reason for study
discontinuation, with a similar incidence across
treatments (12.1–13.5%). Approximately 60% of
patients had documented use of an ICS, either alone
or in combination before entering the study. The
percentage of patients who discontinued from the
study in the formoterol and placebo groups was
slightly higher in patients previously treated with
ICS (34.9% and 38.0%, respectively) compared
with those not previously receiving ICS before the
study (26.8% and 33.9%, respectively). In contrast,
patients in the budesonide/formoterol 320/9-mg
group previously receiving ICS had a lower discon-
tinuation rate compared with those not previously
receiving ICS (23.1% vs 34.1%, respectively). In the
budesonide/formoterol 160/9-mg group, the percent-
age of patients who discontinued the study was
similar for those who were previously receiving an
ICS (29.5%) and those who were not (28.2%).
Most demographic and disease characteristics at
baseline were similar across treatments (table I).
However, in the serial spirometry subset (n= 491),
mean percentage reversibility was greater in the
budesonide/formoterol 320/9 mg (19.9%), budeso-
nide/formoterol 160/9 mg (20.7%) and placebo
(19.5%) groups versus formoterol (16.9%). COPD
severity[1] was moderate in 17.8%, severe in 60.4%
and very severe in 21.5% of patients. Common co-
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morbid conditions included hypertension (41.6%),
lipid profile abnormalities (22.0%), cardiac disease
(17.7%), diabetes mellitus (11.0%), osteoporosis
(10.5%), cataracts (5.2%), atrial fibrillation/arrhyth-




Improvements in pre-dose FEV1 were signifi-
cantly greater for budesonide/formoterol 320/9mg
compared with formoterol (primary comparison;
p= 0.008) and for both budesonide/formoterol dos-
ages compared with placebo (p< 0.001) [figure 3a].
Although improvements in 1-hour post-dose FEV1
were significantly greater for both budesonide/for-
moterol dosages compared with placebo (primary
comparison; p< 0.001), budesonide/formoterol 320/
9mg also resulted in significantly greater improve-
ments comparedwith formoterol (p= 0.023) [figure
3b]. Improvements from baseline were apparent at
the first assessment (pre-dose FEV1 at end of month
1; 1-hour post-dose FEV1 at day of randomization)
and overall maintained over the 12-month treatment
period for both budesonide/formoterol dosages (fig-
ure 3a and b).
Secondary Assessments
Morning and evening PEF improved significant-
ly for all active treatments compared with placebo
(p£ 0.012) and for both budesonide/formoterol dos-
ages compared with formoterol (p £ 0.017) [table
II]. Results for pre-dose and 1-hour post-dose FVC
are presented in the online supplement (see figures
S1a and b in the supplementary material [‘Ar-
ticlePlus’] at http://links.adisonline.com/DGZ/A5).
In the serial spirometry subset, a ‡15% improve-
ment in FEV1was observed at 5minutes after dose















(n = 494) 
Took study med
(n = 494) 
Took study med
(n = 495) 
Took study med
(n = 481) 
Took study med
(n = 1964) 
Discontinued
(n = 175) 
Completed
(n = 360) 
Completed
(n = 306) 
Screened (N = 2816)
Randomized (n = 1964)
Failed screening (n = 852)
• Eligibility criteria not fulfilled (n = 528)
• Consent withdrawn (n = 180)
• AE (n = 94)
• Other (n = 29)
• Lost to follow-up (n = 21)
• Eligibility criteria not 
fulfilled (n = 10)
• AE (n = 65)
• Consent withdrawn 
(n = 77)
• Lost to follow-up 
(n = 13) 
• Other (n = 10)
Discontinued
(n = 157) 
Completed
(n = 338) 
• Eligibility criteria not 
fulfilled (n = 14)
• AE (n = 65)
• Consent withdrawn 
(n = 52)
• Lost to follow-up 
(n = 12) 
• Other (n = 14)
Discontinued
(n = 143) 
Completed
(n = 351) 
• Eligibility criteria not 
fulfilled (n = 8)
• AE (n = 65)
• Consent withdrawn 
(n = 45)
• Lost to follow-up 
(n = 12) 
• Other (n = 13)
Discontinued
(n = 134) 
• Eligibility criteria not 
fulfilled (n = 10)
• AE (n = 60)
• Consent withdrawn 
(n = 41)
• Lost to follow-up 
(n = 9) 
• Other (n = 14)
Discontinued
(n = 609) 
Completed
(n = 1355) 
• Eligibility criteria not 
fulfilled (n = 42)
• AE (n = 255)
• Consent withdrawn 
(n = 215)
• Lost to follow-up 
(n = 46) 
• Other (n = 51)
Fig. 2. Patient disposition. AE = adverse event; bid = twice daily; BUD = budesonide; DPI = dry powder inhaler; FM = formoterol;
med = medication; PL = placebo; pMDI = pressurized metered-dose inhaler.
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treatments on the day of randomization (budeso-
nide/formoterol 320/9 mg, 17.7%; budesonide/
formoterol 160/9 mg, 20.3%; formoterol 9 mg,
16.5%) and at end of treatment (budesonide/formo-
terol 320/9mg, 21.8%; budesonide/formoterol 160/
9 mg, 22.4%; formoterol 9 mg, 15.0%) [figures 4a, b
and c]. There was no evidence of a diminished effect
at end of treatment over the 12-hour period in the
budesonide/formoterol groups. Mean FEV1 at
12 hours and baseline-adjusted average 12-hour
FEV1 were significantly improved with both budes-
onide/formoterol dosages compared with placebo on
the day of randomization and at end of treatment
(p £ 0.002) [table II]. Although both budesonide/
formoterol dosages demonstrated significant im-
provements inmeanFEV1 at 12 hours and in base-
line-adjusted average 12-hour FEV1 compared with
formoterol on the day of randomization (p£ 0.029),
only budesonide/formoterol 320/9mg demonstrated
this effect at the end of treatment (p £ 0.004)
[table II].
No significant differences in pre-dose IC were
observed among the treatment groups (figure 5a).
Improvements from baseline to the average over the
randomized treatment period in 1-hour post-dose
ICwere significantly greater with both budesonide/
formoterol dosages compared with placebo
(p < 0.001) and formoterol (p £ 0.018) [figure 5b].
Table I. Patient demographic and baseline clinical characteristics of randomized patients











































habitual smokera [n] (%)


















Months since first COPD symptoms [mean] (SD) 125 (80.6) 133 (92.1) 135 (87.2) 127 (84.5)





















Percentage predicted FEV1 at screening
(postbronchodilator) [mean] (SD)
38.6 (11.4) 39.6 (10.9)c 39.3 (11.9)d 40.8 (11.5)e
FEV1 (L) at baseline
f (prebronchodilator) [mean] (SD) 1.0 (0.4) 1.0 (0.4) 1.0 (0.4) 1.1 (0.4)
a Smokes at least one cigarette/day and has been smoking for ‡1 year before screening.
b Smokes less than one cigarette/day or has been smoking for <1 year before screening or stopped smoking within 6 months before
screening.
c n = 493.
d n = 494.
e n = 480.
f Baseline is defined as the last pre-dose FEV1 value before the first dose of randomized treatment period.
bid = twice daily; BUD = budesonide; COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; FEV1 = forced expiratory
volume in 1 second; FM = formoterol; pMDI = pressurized metered-dose inhaler.
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Both dosages of budesonide/formoterol resulted in a
350mL (»25%) improvement from baseline to the
average over the randomized treatment period in 1-
hour post-dose IC, and formoterol resulted in a
210mL (17%) improvement in 1-hour post-dose IC.
Chronic Obstructive Pulmonary Disease
(COPD) Exacerbations
Time to first COPD exacerbationwas significant-
ly prolongedwith both budesonide/formoterol dos-
ages compared with placebo (p £ 0.004) and with
budesonide/formoterol 320/9mg comparedwith for-
moterol (p = 0.026) [figure 6]. In addition, signif-
icant reductions in the overall number of exacerba-
tions per patient-treatment year were observed with
budesonide/formoterol 320/9mg and 160/9mg ver-
sus placebo (37% and 41%, respectively; p< 0.001)
and formoterol (25% and 29%, respectively;
p £ 0.004) [see figure S2 in the supplementary
material]. These reductions were driven by exacer-
bations treated with oral corticosteroids, the rate of
which was reduced with budesonide/formoterol
320/9 mg and 160/9 mg versus placebo (37.5% and
42.9%, respectively) and formoterol (24.1% and
30.6%, respectively) [p £ 0.006]. In addition, the
percentage of patients in the budesonide/formoterol
320/9mg, budesonide/formoterol 160/9mg, formo-
terol and placebo groups who experienced an exac-
erbation was greater in those receiving ICS therapy
either alone or in combination before the study
(33.7%, 38.2%, 39.9% and 40.1%, respectively)
compared with those not previously receiving ICS
(25.8%, 24.9%, 29.4% and 32.8%, respectively).
Health Status and COPD Symptoms
Improvements in SGRQ total scorewere signifi-
cantly greater for both budesonide/formoterol dos-
ages compared with placebo (p £ 0.006) and for
budesonide/formoterol 160/9mg comparedwith for-
moterol (p = 0.006; table III). The improvements
from baseline in SGRQ total score in the active
treatment groups were not clinically meaningful
versus placebo (i.e. decrease of ‡4 points). Signifi-
cantly greater improvements in COPD symptom
variables were observed for both budesonide/formo-
terol dosages versus placebo for all variables
(BCSS, dyspnoea score, cough score, sputum score,
sleep score, percentage of awakening-free nights
and total daily rescue medication use) [p £ 0.003].
Compared with formoterol, mean improvements
were significantly greater with budesonide/formo-
terol 320/9 mg (p £ 0.038) for all COPD symptom
variables except sputum score and percentage of
awakening-free nights, and with budesonide/
formoterol 160/9 mg (p £ 0.047) for all COPD
symptom variables except BCSS, dyspnoea and spu-














































































BUD/FM pMDI 320/9 μg
BUD/FM pMDI 160/9 μg
FM DPI 9 μg
Placebo   
BUD/FM pMDI 320/9 μg
BUD/FM pMDI 160/9 μg
FM DPI 9 μg































Fig. 3. Co-primary efficacy endpoints. Least squares mean change
from baseline by study visit over the randomized treatment period
in (a) pre-dose forced expiratory volume in 1 second (FEV1) and (b)
1-hour post-dose FEV1. BUD = budesonide; DPI = dry powder
inhaler; FM = formoterol; pMDI = pressurized metered-dose inhal-
er. * p <0.001 vs placebo; - p £0.023 vs FM.
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Improvements (i.e. reductions) in dyspnoea
scores were significantly greater for all active treat-
ments versus placebo (p £ 0.003) and for budes-
onide/formoterol 320/9 mg versus formoterol
(p = 0.032; table IV). All active treatment arms
demonstrated‡0.2 points (minimal important differ-
ence) change from baseline, but only budesonide/
formoterol 320/9mg had an increase of ‡0.2 points
over placebo. A significantly (p < 0.001) greater
percentage of patients in both budesonide/formoter-
ol groups and in the formoterol group experienced
clinically meaningful improvements in dyspnoea
versus placebo (see figure S3 in the supplementary
material).
Safety Evaluations
Mean treatment exposure was lowest for placebo
(270 days) compared with budesonide/formoterol
320/9 mg (305 days), budesonide/formoterol 160/
9 mg (299 days) and formoterol (289 days). The
most commonly reported AE (irrespective of causal-
ity) was COPD, which had a lower incidence with
Table II. Mean (SD) changes from baseline in additional pulmonary function assessments
Variable BUD/FM pMDI FM DPI Placebo




n 121 121 124 125
baselineb 1.02 (0.40) 0.97 (0.39) 1.00 (0.38) 1.02 (0.43)
mean change (baseline adjusted) 0.20 (0.21)*- 0.17 (0.21)*- 0.12 (0.15)* 0.03 (0.15)
End of treatment
n 121 120 124 125
baselineb 1.02 (0.40) 0.97 (0.40) 1.00 (0.38) 1.02 (0.43)
mean change (baseline adjusted) 0.19 (0.32)*- 0.16 (0.27)* 0.10 (0.20)* -0.00 (0.21)
FEV1 at 12 h
a [L]
Day of randomization
n 121 121 124 125
baselineb 1.02 (0.40) 0.97 (0.39) 1.00 (0.38) 1.02 (0.43)
mean change 0.14 (0.25)*- 0.10 (0.20)*- 0.04 (0.15) 0.02 (0.19)
End of treatment
n 121 120 124 125
baselineb 1.02 (0.40) 0.97 (0.40) 1.00 (0.38) 1.02 (0.43)
mean change 0.12 (0.31)*- 0.09 (0.28)* 0.03 (0.21) –0.02 (0.26)
Morning PEF [L/min]























a FEV1 measurements were performed in the subset of patients undergoing serial spirometry testing (n = 491).
b Baseline is defined as the last pre-dose FEV1 value before the first dose of the randomized treatment period.
c Baseline is defined as the mean of all values obtained during the last 10 days of the run-in period.
d Mean change from baseline to the average over the randomized treatment period.
bid = twice daily; BUD = budesonide; DPI = dry powder inhaler; FEV1 = forced expiratory volume in 1 second; FM = formoterol;
pMDI = pressurized metered-dose inhaler; PEF = peak expiratory flow. * p< 0.05 vs placebo; - p < 0.05 vs FM DPI 9mg bid; z p < 0.05 vs
BUD/FM 160/9 mg bid.
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budesonide/formoterol 320/9mg versus placebo and
a slightly higher incidence with budesonide/formo-
terol 160/9mg versus placebo (table V). AEs consid-
ered by the investigator to be related to studymed-
ication were generally similar among treatment
groupswith themost commonly reported being oral
candidiasis, COPD and dysphonia (see table SI in
the supplementary material).
The total incidence of pneumonia-related AEs
(pneumonia, bronchopneumonia, lobar pneumonia
and pneumonia staphylococcal) was similar for
budesonide/formoterol 320/9 mg and 160/9 mg
(4.0% and 3.4%, respectively) compared with for-
moterol (3.4%) and placebo (5.0%) [see table SII in
the supplementarymaterial]. For potential lung in-
fections other than pneumonia, the incidence was
slightly higher in the active treatment groups versus
placebo, which was driven largely by bronchitis (see
table SII in the supplementary material). AEs typi-
cally or potentially associated with local and sys-
temic effects of inhaled corticosteroids (local ef-
fects: aphonia, dysphonia, oral candidiasis and can-
didiasis; systemic effects: weight gain, adrenal
suppression, ocular effects, skin effects, psychiatric
disorder, diabetes control, thirst, taste effects and
bone effects) were more frequent with budesonide/
formoterol 320/9mg (10.3% and 4.0%, respectively)
and budesonide/formoterol 160/9 mg (5.7% and
4.5%, respectively) than formoterol (0.6% and
2.6%, respectively) and placebo (2.5% and 2.7%,
respectively). The overall incidence of LABA class
effects (i.e. tremor, palpitation, tachycardia, potassi-
um changes, glucose changes, headache, agitation,
anxiety, sleep effects and muscle cramp) was low,
but higher among active treatment groups (budeso-
nide/formoterol 320/9 mg [9.5%], budesonide/for-
moterol 160/9 mg [8.9%] and formoterol [6.5%])
versus placebo (4.8%). The incidence of cardiac-
related AEs was higher for all active treatments
(10.5–11.3%) versus placebo (6.9%). The most
common cardiac-relatedAEswere hypertension and
angina pectoris (budesonide/formoterol 320/9 mg
[2.4% and 1.2%, respectively], budesonide/formo-
terol 160/9 mg [1.6% and 0.8%, respectively], for-
moterol [2.6% and 1.8%, respectively] and placebo
[2.1% and 1.0%, respectively]). Although the num-
ber of atrial fibrillation AEs was low, all cases
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Fig. 4. Mean percentage change from baseline in forced expir-
atory volume in 1 second (FEV1) over 12 hours at randomization
and end of treatment (EOT) for (a) budesonide (BUD)/formoterol
(FM) 320/9 mg twice daily (bid) vs placebo, (b) BUD/FM 160/9 mg
bid vs placebo and (c) FM 9 mg bid vs placebo. DOR = day of
randomization; DPI = dry powder inhaler; pMDI = pressurized me-
tered-dose inhaler.
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Discontinuations due to AEs (DAEs) occurred in
238 patients, with a similar incidence observed
across treatment groups (range 11.3–12.5%) [see
table SIII in the supplementarymaterial]. Themost
commonDAEwasCOPD,whichwas highest in the
formoterol group (7.3%) and lowest in the budeso-
nide/formoterol 320/9 mg group (4.0%); the inci-
dence was similar in the budesonide/formoterol 160/
9 mg (6.1%) and placebo (6.0%) groups (see table
SIII in the supplementary material). The overall
incidence of non-fatal serious adverse events
(SAEs) was highest with formoterol (17.8%) com-
pared with the other treatment groups and higher
with budesonide/formoterol 320/9mg (15.6%) and
budesonide/formoterol 160/9 mg (13.6%) versus
placebo (12.1%) [see table SIV in the supplementa-
ry material]. The most common non-fatal SAEs
(occurring in five or more patients [all treatment
groups combined]) were COPD (6.8%), pneumonia
(1.5%), atrial fibrillation (0.5%), angina pectoris
(0.3%), bronchitis (0.3%) and coronary artery dis-
ease (0.3%). These non-fatal SAEs occurred at a
similar incidence in all treatment groups, except for
COPD, which was slightly more common in the
active treatment groups (budesonide/formoterol
320/9 mg [7.1%], budesonide/formoterol 160/9 mg
[6.7%] and formoterol [7.9%]) versus placebo
(5.6%). Fifteen patients died during the randomized
treatment period with no imbalance across treat-
ments: three in the budesonide/formoterol 320/9mg
group; six in the budesonide/formoterol 160/9 mg
group; two in the formoterol group; and four in the
placebo group. Fifteen patients died after the ran-
domized treatment period (‡2 days after stopping
study treatment) with no imbalance across treat-
ments: five in the budesonide/formoterol 320/9 mg
group; two in the budesonide/formoterol 160/9mg
group; four in the formoterol group; and four in the
placebo group.None of the deaths were considered
drug related by the investigator.
Clinically significant changes in vital signs, 24-
hour urinary cortisol, and 12-lead ECGs, QT inter-
val andHolter assessments were rare. The geometric
mean values of 24-hour urinary cortisol at 6months
and end of treatmentwere lower in both budesonide/
formoterol dosage groups comparedwith formoterol
and placebo (see table SV in the supplementary
material). Significant differences in 24-hour urinary
cortisol were observed between the budesonide/for-
moterol 320/9mg and placebo groups (p= 0.035) at
month 6 and between the budesonide/formoterol
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Fig. 5. Least squares mean change from baseline by study visit
over the randomized treatment period in (a) pre-dose inspiratory
capacity (IC) and (b) 1-hour post-dose IC. BUD = budesonide;
DPI = dry powder inhaler; FM = formoterol; pMDI = pressurized
metered-dose inhaler. * p <0.001 vs placebo; - p = 0.01 vs FM;
z p< 0.05 vs FM; y p <0.01 vs placebo.
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Corrected QT (QTc) intervals ‡450msec were
experienced by similar percentages of patients
across all treatment groups, whereas few patients
experienced QTc intervals ‡500msec or a QTc
change ‡60msec (see table SVI in the supplementa-
ry material). Data fromECG andHolter recordings
showed a similar incidence of new onset atrial fibril-
lation in the active and placebo groups.
BMDwas stable over the 1-year study period in
all treatment groups, with small but statistically
significant differences in changes from baseline ob-
served for budesonide/formoterol 320/9mg com-
paredwith all other treatments for total lumbar spine
BMD (p£ 0.037) and for budesonide/formoterol
320/9mg versus formoterol for total hip BMD
(p= 0.012) [see table SVII in the supplementary
material]. The differences between the treatment
groups in changes from baseline in BMD were of
unclear clinical relevance, as the geometric least
squares mean ratios for these treatment group com-
parisons were close to 1 (range 0.98–0.99).
Minor increases in lenticular opacities and
intraocular pressure were noted across all treatment
groups in the ophthalmological analysis subset; the
magnitude of these changes was similar among the
treatment groups (see table SVIII in the supplemen-
tary material). Small but significant differences
were observed for the change from baseline in pos-
terior subcapsular score between the budesonide/
BUD/FM pMDI 320/9 μg
BUD/FM pMDI 160/9 μg




























Fig. 6. Kaplan-Meier probability curve for the time to first chronic
obstructive pulmonary disease exacerbation during randomized
treatment. BUD = budesonide; DPI = dry powder inhaler; FM =
formoterol; pMDI = pressurized metered-dose inhaler. * p £0.004
vs placebo; - p = 0.026 vs FM.
Table III. Mean changes (SD) in SGRQ total and domain scores from baselinea to end of treatmentb
Score BUD/FM pMDI FM DPI Placebo
320/9 mg bid 160/9mg bid 9 mg bid
Total score
n 442 453 446 408
Baseline 54.6 (17.4) 55.7 (16.7) 55.1 (16.4) 54.7 (16.1)
Mean change –3.9 (13.5)* –5.3 (13.7)*- –2.9 (13.3) –1.5 (12.7)
Symptoms domain
n 461 470 460 431
Baseline 66.8 (20.0) 67.2 (18.0) 65.6 (19.2) 66.3 (18.1)
Mean change –7.9 (19.9)*- –7.4 (19.4)* –4.6 (19.9) –2.8 (19.2)
Activity domain
n 452 467 454 415
Baseline 68.6 (19.9) 70.8 (18.2) 70.1 (17.6) 69.5 (18.1)
Mean change –2.3 (14.9)* –3.9 (15.9)* –2.1 (15.0) –0.5 (15.5)
Impacts domain
n 458 464 458 421
Baseline 42.9 (20.0) 43.4 (19.8) 43.3 (19.8) 42.5 (18.8)
Mean change –3.6 (16.4)* –5.3 (16.3)*- –2.8 (15.8) –1.4 (15.0)
a Baseline defined as the last assessment before the first dose of randomized treatment.
b End of treatment defined as the last assessment during randomized treatment.
bid = twice daily; BUD = budesonide; DPI = dry powder inhaler; FM = formoterol; pMDI = pressurized metered-dose inhaler; SGRQ = St
George’s Respiratory Questionnaire. * p < 0.05 vs placebo; - p < 0.05 vs FM DPI 9 mg bid.
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formoterol groups (p= 0.022). Clinically significant
changes in ophthalmological assessment were infre-
quent.
Discussion
In this study, both budesonide/formoterol dosage
strengths resulted in significant improvements from
baseline over the randomized treatment period in
pulmonary function, health status andCOPDsymp-
toms, as measured by dyspnoea, cough and sputum
production, and a clinically significant reduction in
COPD exacerbation rate compared with placebo. In
addition, both budesonide/formoterol pMDI dos-
ages were well tolerated relative to formoterol alone
and placebo.
The results of this 12-month study confirm those
from the earlier related 6-month study by Tashkin et
al.[4] and are consistent with those from studies of
budesonide/formoterol DPI.[2,3] Taken together, the
results demonstrate that this ICS/LABA combina-
tion provides benefits beyond formoterol alone in
the treatment ofCOPD.The contribution of budeso-
nide to improvements from baseline in pulmonary
function and COPD symptoms was demonstrated
by the greater efficacy of budesonide/formoterol
320/9mg compared with formoterol alone for the co-
Table IV. Mean (SD) changes in chronic obstructive pulmonary disease (COPD) symptom variables from baselinea to the average over the
randomized treatment period
Variable BUD/FM pMDI FM DPI Placebo
320/9 mg bid 160/9mg bid 9 mg bid
BCSS [0–12]
n 489 488 489 467
Baseline 5.4 (2.1) 5.5 (2.0) 5.4 (2.0) 5.3 (2.1)
Mean change –0.8 (1.8)*- –0.8 (1.7)* –0.6 (1.6)* –0.3 (1.7)
Dyspnoea score [0–4]
n 489 488 489 467
Baseline 2.16 (0.67) 2.15 (0.71) 2.15 (0.68) 2.11 (0.71)

















































































a Baseline is defined as the mean of all values obtained during the last 10 days of the run-in period.
b Night with a sleep score of 0.
bid = twice daily; BCSS = Breathlessness Cough and Sputum Scale; BUD = budesonide; DPI = dry powder inhaler; FM = formoterol;
pMDI = pressurized metered-dose inhaler. * p< 0.05 vs placebo; - p< 0.05 vs FM DPI 9 mg bid.
Budesonide/Formoterol in One HFA pMDI for COPD 561
ª 2009 Adis Data Information BV. All rights reserved. Drugs 2009; 69 (5)
primary variables of pre-dose FEV1 and 1-hour
post-dose FEV1, and for dyspnoea and total BCSS
scores, supporting use of the higher-dose combina-
tion for COPD symptoms. Both budesonide/formo-
terol dosage strengths demonstrated greater im-
provements from baseline compared with formoter-
ol alone in morning and evening PEF, 12-hour
FEV1, symptom scores and rescue medication use.
In addition, the 25–29% reduction in exacerba-
tion rate observed with both budesonide/formoterol
dosage strengths beyond the substantial reduction
achievedwith formoterol alone further demonstrates
the important contribution of budesonide to the
combination product. The magnitude of the reduc-
tion in exacerbation rates reported in this study is
similar to that reported previously for fixed-dose
regimens of budesonide/formoterol 320/9mg twice
daily[2-4] and fluticasone propionate/salmeterol[11-13]
relative to LABA alone. A key difference between
this 12-month study and the 6-month study of simi-
lar design reported by Tashkin et al.[4] is that this
study was powered to show a difference in exacer-
bations, while the 6-month studywas not. This study
demonstrated a significant reduction in exacerbation
rates in patients treated with budesonide/formoterol
320/9mg and 160/9mg compared with those receiv-
ing formoterol or placebo.
The fact that a greater percentage of patients in
the formoterol and placebo groups who previously
received ICS therapy, either alone or in combina-
tion, experienced exacerbations compared with
those who did not previously receive ICS therapy
may result in a skewing of the data; however, a
similar response was observed in combination
budesonide/formoterol patients with a greater per-
centage of patients who previously received ICS
experiencing exacerbations compared with patients
who were not previously treated with ICS therapy.
Similarly, a greater percentage of patients who pre-
viously received ICS therapy discontinued in the
formoterol and placebo groups than those who did
not previously receive ICS therapy; however, this
trend was reversed in the combination budesonide/
formoterol groups.
The long-term nature of this study allowed for a
more thorough assessment of tolerability compared
with the 6-month study.[4] No differences in pneu-
monia incidence were observed among treatment
groups in this study or in the 6-month study, despite
a shorter exposure time in the placebo group.[4]
These results contrast with previous COPD studies
Table V. Overall adverse events (AEs) [irrespective of relationship to study medication] reported by ‡3% of patients








Mean exposure [days] (SD) 305 (115) 299 (118) 289 (127) 270 (139)
AE [n] (%)
‡1 AE 322 (65.2) 323 (65.4) 299 (60.4) 268 (55.7)
COPD 66 (13.4) 93 (18.8) 83 (16.8) 77 (16.0)
Nasopharyngitis 35 (7.1) 44 (8.9) 30 (6.1) 22 (4.6)
Bronchitis 24 (4.9) 22 (4.5) 24 (4.8) 18 (3.7)
Viral URTI 21 (4.3) 22 (4.5) 22 (4.4) 17 (3.5)
Pneumonia 15 (3.0) 15 (3.0) 17 (3.4) 23 (4.8)
Oral candidiasis 36 (7.3) 21 (4.3) 2 (0.4) 8 (1.7)
Sinusitis 19 (3.8) 19 (3.8) 19 (3.8) 8 (1.7)
Back pain 18 (3.6) 5 (1.0) 14 (2.8) 11 (2.3)
URTI 14 (2.8) 16 (3.2) 10 (2.0) 5 (1.0)
Muscle spasms 16 (3.2) 16 (3.2) 4 (0.8) 6 (1.2)
Dysphonia 16 (3.2) 6 (1.2) 1 (0.2) 4 (0.8)
bid = twice daily; BUD = budesonide; COPD = chronic obstructive pulmonary disease; DPI = dry powder inhaler; FM = formoterol;
pMDI = pressurized metered-dose inhaler; URTI = upper respiratory tract infection.
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that showed an increased incidence of pneumonia
with fluticasone propionate/salmeterol treat-
ment.[11-14] However, in this study and the 6-month
study,[4] the incidence of potential lung infections
other than pneumonia was slightly higher in all
active treatments compared with placebo; these dif-
ferences were largely driven by an increased inci-
dence of bronchitis. The incidence of SAEs, includ-
ing COPD SAEs, was slightly higher in both
budesonide/formoterol groups comparedwith place-
bo. This finding may be attributed to the earlier
discontinuation in the placebo group, which resulted
in a shorter study drug exposure (35 and 29 fewer
days vs budesonide/formoterol 320/9mg and 160/
9mg, respectively). Although the overall incidence
of atrial fibrillation, a known LABA class effect,
was small (1.1%), an imbalance was noted between
the formoterol-containing arms and placebo. How-
ever, no differences in new-onset atrial fibrillation
were apparent among groups based on 24-hour
Holtermonitoring or ECGdata collected at repeated
visits during the randomized treatment period. Over-
all, the safety profile of budesonide/formoterol
pMDI in this 12-month study was similar to that
reported in the 6-month study by Tashkin et al.,[4]
suggesting no increase in safety concerns with a
longer duration of treatment.
Conclusions
Both dosage strengths of budesonide/formoterol
pMDI (320/9mg and 160/9mg) were effective and
well tolerated over 1 year of treatment in this popu-
lation of patients with moderate to very severe
COPD. In addition, budesonide/formoterol pMDI
320/9mg demonstrated greater efficacy compared
with formoterol for pre-dose FEV1, suggesting that
the higher dosage strength containing twice the daily
dose of budesonide is appropriate in this patient
population.
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